A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatmen

Study Description

SCOT is a clinical research study designed for people with severe forms of scleroderma. SCOT stands for Scleroderma: Cyclophosphamide Or Transplantation. The SCOT study will compare the potential benefits of stem cell transplant and high-dose monthly cyclophosphamide (Cytoxan) in the treatment of scleroderma.

Study Details

Registry ID:

NCT00114530

Conditions:

Scleroderma, Systemic, Sclerosis, Autoimmune Disease

Phase:

Phase 2,Phase 3

Target Enrollment:

75 participants

Start Date:

June 1, 2005

Age Range:

18–69 years

Healthy Volunteers:

No

Study Locations (17 sites)

• Massachusetts General Hospital
  Boston, MassachusettsUnited States, United States
• Boston University School of Medicine
  Boston, MassachusettsUnited States, United States
• Medical University of South Carolina
  Charleston, South CarolinaUnited States, United States
• Duke University Medical Center
  Durham, North CarolinaUnited States, United States
• University of Pittsburgh
  Pittsburgh, PennsylvaniaUnited States, United States
• University of Kentucky
  Lexington, KentuckyUnited States, United States
• University of Toledo Health Science Campus
  Toledo, OhioUnited States, United States
• University of Michigan
  Ann Arbor, MichiganUnited States, United States
• Medical College of Wisconsin
  Milwaukee, WisconsinUnited States, United States
• Washington University School of Medicine
  Saint Louis, MissouriUnited States, United States
• University of Texas-Houston Medical School
  Houston, TexasUnited States, United States
• MD Anderson Cancer Center
  Houston, TexasUnited States, United States
• Dr. Markland Medical Professional Corporation
  Saskatoon, SaskatchewanCanada, Canada
• City of Hope National Medical Center
  Duarte, CaliforniaUnited States, United States
• UCLA Medical School
  Los Angeles, CaliforniaUnited States, United States
• University of Calgary
  Calgary, AlbertaCanada, Canada
• Fred Hutchinson Cancer Research Center (FHCRC)
  Seattle, WashingtonUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →